Clinical Trials on Melanoma, Ocular

Total 8616 results

Assistance Publique - Hôpitaux de Paris

Unknown

Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas. (NILOMEL)

Stage IV Melanoma | Stage III Melanoma | Amplification | Malignant Skin Melanoma T0

France
Perspective Therapeutics

Recruiting

MC1R-targeted Alpha-particle Therapy Trial in Adults With Advanced Melanoma

Metastatic Melanoma | Melanoma (Skin) | Mucosal Melanoma | Melanoma Stage IV | Melanoma Stage III | Melanoma, Uveal

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI); National Comprehensive Cancer Network

Terminated

Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery

Recurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma (Locally Advanced) | Stage IIC Melanoma (Locally Advanced) | Stage IV Melanoma (Limited, Resectable)

United States
Steinar Aamdal

Terminated

Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma

Metastatic Malignant Melanoma

Norway
Dana-Farber Cancer Institute
Massachusetts General Hospital; Novartis; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital

Completed

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

Melanoma | Acral Melanoma | Mucosal Lentiginous Melanoma

United States
Hoffmann-La Roche

Completed

A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy

Malignant Melanoma, Neoplasms

Belgium, Spain, Germany, Netherlands, Finland
Eli Lilly and Company

Completed

A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma

Metastatic Malignant Melanoma

United States
National Cancer Institute (NCI)

Terminated

Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV

Recurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma

United States
IDEAYA Biosciences

Recruiting

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Colorectal Cancer | Metastatic Uveal Melanoma | Cutaneous Melanoma | Other Solid Tumors

United States, Australia, Canada
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma

Recurrent Melanoma | Stage IV Melanoma | Stage IIIc Melanoma

United States
National Cancer Institute (NCI)

Completed

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

Melanoma | Recurrent Melanoma | Stage IV Melanoma | Stage III Melanoma

United States
National Cancer Institute (NCI)

Terminated

Tanespimycin in Treating Patients With Stage III-IV Melanoma

Recurrent Melanoma | Stage IV Melanoma | Stage III Melanoma

United States
MelanomaPRO, Russia
Novartis

Recruiting

pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE (RATIONALE)

Melanoma | Melanoma Stage IV | Melanoma Stage III

Russian Federation
The Netherlands Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo)

Malignant Melanoma Stage III

Austria, Netherlands, Australia, Sweden
Eisai Inc.
PharmaBio Development Inc.

Completed

Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma

Stage IV Melanoma | Stage IIIC Melanoma

United States
Dana-Farber Cancer Institute
Bristol-Myers Squibb

Withdrawn

A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma

Melanoma Stage IV | Melanoma Stage III

United States
Immutep Australia Pty. Ltd.

Completed

Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma (TACTI-mel)

Stage IV Melanoma | Stage III Melanoma

Australia
National Cancer Institute (NCI)

Completed

Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

Stage IV Melanoma | Stage III Melanoma

United States
National Cancer Institute (NCI)

Terminated

Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma

Melanoma | Malignant Melanoma | Melanoma, Experimental

United States
Mannkind Corporation

Terminated

Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma

Stage IV Melanoma | Stage III Melanoma

United States
Regina Elena Cancer Institute

Recruiting

Versatile Ampification Single-Molecule Detection in Liquid Biopsy (VerSiLiB)

Melanoma (Skin) | Liquid Biopsy | Melanoma Stage IV | Melanoma Stage III | BRAF V600E

Italy
Universitair Ziekenhuis Brussel

Recruiting

A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma (RegoMel)

Melanoma Stage IV | Melanoma Stage III

Belgium
Evaxion Biotech A/S
Merck Sharp & Dohme LLC

Recruiting

A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma

Melanoma Stage IV | Melanoma Stage III

Australia
The Netherlands Cancer Institute

Recruiting

FMT to Convert Response to Immunotherapy

Melanoma Stage IV | Melanoma Stage III

Netherlands
University of California, San Francisco
Array BioPharma

Recruiting

Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma

Melanoma Stage IV | Melanoma Stage III

United States
Pierre Fabre Pharma GmbH
Pierre Fabre Pharma Austria; Pierre Fabre Pharma AG

Recruiting

Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment (BERING)

Melanoma Stage IV | Melanoma Stage III

Austria, Germany, Switzerland
The Netherlands Cancer Institute
Amgen

Active, not recruiting

Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (Stage IIIB/C/D-IV M1a) Melanoma With Injectable Disease (NIVEC)

Melanoma Stage IV | Melanoma Stage III

Netherlands
Universitair Ziekenhuis Brussel

Completed

TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma (TraMel-WT)

Stage IV Melanoma | Stage III Melanoma

Belgium
Melanoma and Skin Cancer Trials Limited
Bristol-Myers Squibb; Amgen; Peter MacCallum Cancer Centre, Australia

Active, not recruiting

Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma (CHARLI)

Melanoma | Melanoma Stage Iv | Melanoma Stage Iii

Australia
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Acral Malignant Melanoma

Advanced Acral Malignant Melanoma

China
National Cancer Institute (NCI)

Terminated

Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma

Stage IV Melanoma | Stage III Melanoma

United States
National Cancer Institute (NCI)

Completed

Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma

Recurrent Melanoma | Stage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Recurrent Intraocular Melanoma | Extraocular Extension Melanoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma

Recurrent Melanoma | Stage IV Melanoma | Stage III Melanoma

United States
National Cancer Institute (NCI)

Completed

Lovastatin in Treating Patients At High Risk of Melanoma

Precancerous Condition | Stage II Melanoma | Stage 0 Melanoma | Stage I Melanoma

United States
National Cancer Institute (NCI)

Terminated

Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery

Unspecified Adult Solid Tumor, Protocol Specific | Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
Inge Marie Svane
Adaptimmune

Not yet recruiting

To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma (ADP-TILIL7)

Melanoma | Melanoma Stage IV | Melanoma Stage III
Taiga Biotechnologies, Inc.

Recruiting

Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors

Stage IV Melanoma | Stage III Melanoma

United States
Lisata Therapeutics, Inc.

Terminated

Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma

Stage IV Melanoma | Stage III Melanoma

United States
The Netherlands Cancer Institute

Unknown

Study With T-cel Receptor Gene Therapy in Metastatic Melanoma (TCR)

Stage IV Skin Melanoma | Eye; Melanoma

Netherlands
Medical University of Vienna

Completed

Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma

Stage IV Melanoma | Stage III Melanoma

Austria
Pierre Fabre Medicament

Recruiting

A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients (TavieSkin)

Metastatic Melanoma | Melanoma (Skin) | BRAF V600 Mutation

Portugal
Dana-Farber Cancer Institute
Massachusetts General Hospital; Pfizer; Beth Israel Deaconess Medical Center

Completed

SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma

Mucosal Lentiginous Melanoma | Acral Lentiginous Malignant Melanoma

United States
Mannkind Corporation

Completed

Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma.

Advanced Melanoma | Stage III and IV Melanoma

United States
Pierre Fabre Medicament
Biotrial

Active, not recruiting

Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations

Melanoma | Metastatic Melanoma | Unresectable Melanoma | BRAF V600 Mutation

France
Syneos Health
Oncolys BioPharma Inc

Unknown

Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma

Melanoma Stage Iv | Melanoma Stage III

United States
Sheba Medical Center

Unknown

Fecal Microbiota Transplantation (FMT) in Metastatic Melanoma Patients Who Failed Immunotherapy

Melanoma Stage Iv | Unresectable Stage III Melanoma

Israel
National Cancer Institute (NCI)

Completed

Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma

Recurrent Melanoma | Stage IV Melanoma | Uveal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Recurrent Intraocular Melanoma | Extraocular Extension Melanoma

Canada, United States
RemeGen Co., Ltd.

Recruiting

A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)

Advanced Melanoma | Melanoma, Stage II | HER2-positive

China
Pierre Fabre Medicament
Biotrial

Completed

Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations

Melanoma | Metastatic Melanoma | Unresectable Melanoma | BRAF V600 Mutation

France
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Ex Vivo-Activated Lymph Node Lymphocytes in Treating Patients With Stage IIIC-IV Melanoma

Stage IIIC Skin Melanoma | Stage IV Melanoma

United States

Clinical Trials on Melanoma, Ocular

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations